Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Jun 18, 2016 in Coronary artery disease | 0 comments

In a nutshell

This paper studied the long-term outcomes from the implantation of a bioresorbable scaffold that releases everolimus in patients with coronary stenosis. The 5-year study found that the scaffold was safe for use. 

Some background

Coronary stenosis refers to narrowing of the blood vessels that supply blood to the heart. This is due to a build-up of substances like cholesterol that form as plaque in the blood vessel. A bioresorbable scaffold is a mesh structure inserted into blood vessels to prevent it from narrowing. The advantage of this is that the scaffold can be reabsorbed by the body. The scaffold releases everolimus (Afinitor), which prevents excessive growth of the blood vessel layer. The long-term effectiveness and safety of this bioresorbable scaffold is unclear. 

Methods & findings

101 patients had the bioresorbable scaffold inserted. Various imaging devices were used to look at the structure of the blood vessel. 53 patients were followed for 5 years.

During the follow-up time, there were no deaths from heart-related causes. The rate of major adverse cardiac event (undesired outcome of treatment, such as heart attack) was 11%. There were 8 incidents where reduced blood flow made it necessary for a repeat procedure to improve blood supply.

The diameter of the blood vessel was unchanged between 6 to 12 months and 60 months. Blood vessel movement was normal in 85% of the scaffold segments. The total plaque (build-up of substances in blood vessels that block flow of blood) decreased from 6 to 12 months to 60 months. The scaffold frames were no longer visible at 60 months. The average lumen area tended to increase from 6 to 12 months to 60 months

The bottom line

The authors concluded that at 5 years after the bioresorbable scaffold implantation, the blood vessel lumen size was stable and the rate of major adverse cardiac event was low. 

Published By :

Journal of the American College of Cardiology

Date :

Feb 23, 2016

Original Title :

A Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis: 5-Year Follow-Up.

click here to get personalized updates